Omalizumab
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Omalizumab: From Asthma to Bronchitis
One-Sentence Summary
Omalizumab is an anti-IgE monoclonal antibody originally used for asthma (including allergic and intrinsic asthma) and idiopathic urticaria. The TxGNN model predicts it may be effective for bronchitis, but direct support is thin: 2 clinical trials were matched (both low relevance) and 7 publications are linked, mostly reviews on asthma and asthma-COPD overlap. The data compiled for this report show stronger evidence for neighbouring predictions, particularly obstructive lung disease and atopic eczema.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Asthma, intrinsic asthma, allergic asthma, idiopathic urticaria (approved indication text is not available in the Singapore licence records) |
| Predicted New Indication | Bronchitis |
| TxGNN Prediction Score | 99.999% |
| Evidence Level | L3 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 6 |
| Recommended Decision | Hold (research question only) |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data are not available in the compiled data. Based on known pharmacology, omalizumab is a humanized monoclonal antibody that binds the constant region of free IgE. This lowers free IgE and reduces FcεRI expression and activation of mast cells and basophils, which dampens allergic airway inflammation. Its efficacy in allergic asthma is well established.
The link to bronchitis is indirect. The supporting papers come from asthma and asthma-COPD overlap populations rather than from bronchitis itself. The "bronchitis" label appears to reflect chronic bronchitis/COPD phenotypes with allergic features, or eosinophilic bronchitis in patients with asthma. The mechanism may therefore apply only to a subset of patients with an allergic, IgE-driven component.
For context, other predictions in the same data are better supported:
- Obstructive lung disease (evidence level L1) rests largely on allergic asthma trials and does not carry over to non-allergic COPD. A COPD-specific Phase 2 trial (NCT07059091, n=334) is recruiting, while an earlier COPD study (NCT00851370) was withdrawn with no participants.
- Atopic eczema / dermatitis (L2) has completed small trials, but results are inconsistent and guidelines place omalizumab behind IL-4/IL-13 agents.
- Bronchial neoplasm, acne keloid, acrodermatitis chronica atrophicans, hydroa vacciniforme, neonatal dermatomyositis and childhood connective-tissue-disease interstitial lung disease have no trials or literature and no plausible mechanism (L5). They are likely graph-proximity artifacts.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02049294 | Phase 2/3 | Completed | 11 | Double-blind, placebo-controlled test of whether omalizumab lets prednisone be reduced in patients with asthma and persistent eosinophilic bronchitis. Very small, and the population is not clearly bronchitis alone. Results not provided. |
| NCT02477332 | Phase 2 | Completed | 382 | Dose-finding study of QGE031 add-on therapy in chronic spontaneous urticaria. Omalizumab's role (investigational or comparator) is unclear, and the match to bronchitis is not established. |
Neither trial supports a Phase 3-level conclusion for bronchitis.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 16222080 | 2005 | Review | Clin Rev Allergy Immunol | Omalizumab reduces free IgE and FcεRI expression, and is efficacious in moderate-to-severe persistent asthma. |
| 30196731 | 2018 | Review | Expert Opin Pharmacother | Management of asthma with smoking-induced airway disease (chronic bronchitis, emphysema, asthma-COPD overlap). Drug treatment is uncertain because these patients are excluded from most trials. |
| 26466493 | 2015 | Review | Masui | Preoperative management of asthma or chronic bronchitis. Omalizumab is mentioned as an option for severe allergic asthma. |
| 17663923 | 2007 | Review | Allergol Immunopathol | Overview of monoclonal antibodies in pediatrics, including allergic disease. |
| 21121874 | 2011 | Clinical safety study | Curr Med Res Opin | Pooled safety analysis of omalizumab in children with allergic asthma. |
| 35369622 | 2022 | Cohort | Postepy Dermatol Alergol | Biologic therapy, including omalizumab, may help middle-aged or older patients with severe allergic asthma-COPD overlap. |
| 31478531 | 2019 | Case report | J Investig Allergol Clin Immunol | Rare case of plastic bronchitis after bronchial thermoplasty. |
No randomized trial in bronchitis is among the linked literature.
Singapore Market Information
All six licences are valid single-ingredient injectables (Xolair). Approved indication text is not available in the records.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16115P | Xolair solution for injection, pre-filled syringe 75 mg/0.5 mL | Injection, solution | Not available |
| SIN16116P | Xolair solution for injection, pre-filled syringe 150 mg/1.0 mL | Injection, solution | Not available |
| SIN17029P | Xolair solution for injection, pre-filled syringe 300 mg/2.0 mL | Injection, solution | Not available |
| SIN17030P | Xolair solution for injection, pre-filled pen 75 mg/0.5 mL | Injection, solution | Not available |
| SIN17031P | Xolair solution for injection, pre-filled pen 150 mg/1.0 mL | Injection, solution | Not available |
A sixth licence, SIN17032P (pre-filled pen 300 mg/2.0 mL), is also valid.
Safety Considerations
- Drug Interactions: Eight interaction records were found. Most are minor: zinc sulfate, zinc acetate, zinc gluconate, zinc chloride, echinacea and vitamin E. One is moderate: omacetaxine mepesuccinate. The remaining record is a pharmacology entry describing the target, immunoglobulin heavy constant epsilon (IgE), rather than an interaction.
Please refer to the package insert for warnings and contraindications, which are not available in the compiled data.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is very high, but direct evidence for bronchitis is weak. The only related trial is a tiny study (n=11) in patients with asthma and eosinophilic bronchitis, and the literature consists of reviews on asthma and asthma-COPD overlap. This remains a research question rather than a candidate for action. If the team wants to pursue the respiratory direction, the obstructive lung disease prediction (L1, driven by allergic asthma data) is better supported, with the COPD-OMA trial (NCT07059091) as the key pending study.
To proceed, the following is needed:
- Results and design details of NCT02049294, and clarification of which bronchitis phenotype (eosinophilic, chronic/COPD-related, allergic) is actually being predicted
- Controlled data in bronchitis populations with an IgE-driven component
- Mechanism of action data and the Singapore package insert (warnings, contraindications, approved indications)
- Readout from the COPD-OMA trial (NCT07059091) to inform non-asthma airway disease
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.